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INTRODUCTION 
Ever since Lane (1) first successfully treated a 
case of hemophilia in 1S40 by means of a blood transfusion, 
this has gradually come to be the treatment of choice for 
handling bleeding crises in hemophiliac patients. 
At the present time hemophiliac patients at the 
time of a bleeding crisis are either given fresh plasms or 
fresh frozen plasms because it has been felt that plasma 
stored in some other way rapidly loses its AHG* activity 
(2t6). However, with respect to this there has, in recent 
years, evolved quite a controversy among different investi¬ 
gators. One group of investigators (7-13)in the past few 
years have reported that AHG activity is more stable under 
the usual storage methods of blood bank blood than was 
formerly thought. If this is the case, it would be of great 
value in the treatment of hemophiliac patients since it would 
both insure a readily accessable supply of AHG and would 
substantially reduce the cost involved in maintaining adequat 
supplies of fresh frozen plasma. If AHG activity is stable 
under normal storage conditions, one could effectively use 
plasma for transfusing hemophiliac patients that is often 
discarded when packed cells are used for blood transfusions 
* Anti hemophilic globulin. 
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or plasma that is discarded after blood has been stored for 
more than three weeks. Also it would make available a 
source of AHG at all hospitals and would eliminate the need 
of a central clearing agency that is now required for the 
preparation and distribution of fresh frozen plasma. There- 
fore, it was felt that the importance of studying the storage 
stability of AHG activity was a very pressing issue, and for 
this reason, this study was undertaken. 
Much of the controversy over the storage stability 
of AHG activity has been caused by the fact that until recent 
years, oxalate instead of an acid citrate dextrose solution, 
has been used as a blood anticoagulant. Spaet ($) has shown 
that oxalated blood rapidly loses its AHG activity in sharp 
contrast to blood stored with ACD, which retains AHG activity 
for a considerable length of time when stored at 4° centigrade. 
Other factors in the collection and storage of 
blood besides the type of anticoagulant used have been found 
to play a part in the amount of AHG activity preserved. 
These have included the type of container used (10) and the 
care in the collection of the blood (13). 
Another factor that has added to the confusion in 
this matter of AHG activity of stored blood has been the wide 
diversity of methods used to investigate the amount of AHG 
activity present in a particular blood sample. These methods 
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3 
have included clotting time, prethrombin consumption time 
and the thromboplastin generation test. 
Because of these many varied factors the picture 
regarding the storage stability of AHG activity has become 
greatly confused. This present study was an attempt to 
clarify the picture somewhat by acertaining the storage 
stability of AHG activity of blood collected under various 
conditions and stored at 4° centigrade. 
In the belief that small clots occurring during 
the collection of the blood might play a part in the storage 
stability of AHG activity, half of the blood samples were 
collected after the donar had received intravenous heparin. 
Also included is a study of AHG activity of 
random blood bank samples and an attempt to correlate these 
findings with those of the study mentioned above. 
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METHODS AND MATERIALS 
Blood was collected from four subjects with known 
normal prothrombin consumption by means of a standard poly¬ 
ethylene blood donor tube with the blood being collected in 
quantities of 20 ml. and placed in appropriate storage con¬ 
tainers under sterile conditions. It was then stored for 
varying lengths of time and then AHG assays were done accord¬ 
ing to a slight modification of the method of Spaet (14)» 
Collection and Storage of Blood. 
Series I. Blood was collected from a normal donor 
by means of a number 16 needle and polyethylene tubing 
directly into ten 20 ml. sterile glass test tubes in which 
a vacuum had been created. Half of these tubes contained 
3 ml. of 0.2M ACD* and the other half 2 ml. of 1.0 per cent 
versene. Four of the samples, two with ACD and two with 
versene, were manually agitated for five minutes. Two of 
these agitated samples, one with ACD and one with versene 
were then centrifuged for five minutes at 2000 revolutions 
per minute and the plasma removed and placed in sterile glass 
test tubes. The four samples were then stored at 4° centigrade. 
Four more of the original samples, two with ACD and two with 
* Acid citrate dextrose solutions used for these studies 
contained: 2.45 grams dextrose; 0.3 grams citric acid; 22 
grams orisodium citrate per 100 
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5 
versene, were centrifuged for five minutes at 2000 revolu¬ 
tions per minute and the plasma removed and placed in sterile 
test tubes. Two of these samples, one with ACD and one with 
versene, were stored at 4° centigrade and the other two were 
frozen. The remaining two original samples were stored at 
4° centigrade. 
Series II. Blood was collected from the same 
donor and treated in the same way as in Series I except that 
the donor was given 10 mg. of heparin intravenously five 
minutes before the blood was collected. 
Series III. The same procedure as for Series I 
was used except that a different donor was used. 
Series IV. The same procedure as for Series I was 
used except that a different donor was used. 
Series V. The same procedure as for Series I was 
used except for the following changes: 
1. Blood samples were collected in siliconized 
tubes. 
2. Samples receiving agitation were not included 
in this series. 
3. A different donor was used. 
Series VI. The same procedure as for Series II 
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Series VII. The same procedure as for series I 
was used except for the following changes: 
1. Blood samples were collected in plastic bags. 
2. Samples receiving agitation were not included 
in this series. 
3. A different donor was used. 
Series VIII. The same procedure as for Series II 
was used except for the changes noted in Series VII. 
AHG Assay Technique 
After the blood samples had been stored for three 
weeks AHG assays were done as follows: 
Five one hundreds ml. of the test plasma was added 
to 2.5 ml. of freshly drawn blood of a known hemophiliac 
patient whose prothrombin consumption was known to be 
stable at a level of 65 per cent for a period of six 
months. The blood was then allowed to clot and was 
placed in a water bath at a temperature of 37° centi¬ 
grade for four hours. The serum was then separated 
by centrifuging and was added to 0.2M sodium citrate 
so that the final solution contained one part sodium 
citrate to nine parts serum. This was done to pre¬ 
vent further utilization of prothrombin. This solu¬ 
tion was then incubated in a water bath at a temperature 
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7 
of 37° centigrade for thirty minutes to destroy the 
excess thrombin and was then subjected to prothrombin 
determinations according to the method of Stefanini 
and Crosely (15). 
The above concentration of test plasma was used 
because of reports by Spaet (14) and Mersky (16) that con- 
centrations of one to two per cent fresh frozen citrated 
plasma are needed in order to make the prothrombin consumption 
test of hemophiliac patients normal. 
Determinations for AHG activity by this means were 
made on the samples at different time intervals ranging from 
three to six weeks, 
AHG Assay of Stored Blood Bank Blood 
Random samples of plasma were taken from stored 
whole Blood Bank blood that had been collected at Hartford 
and New Haven and had been stored for periods ranging from 
three to six weeks and AHG assays were done as described 
above. All the blood was stored in glass containers and 
contained ACD as an anticoagulant. 
Conversion of Prothrombin Consumption to AHG Activity 
Fresh citrated plasma was diluted with saline in 
different concentrations so that when it was added to 2,5 ml. 
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of blood from the hemophiliac patient, the final concentra¬ 
tion of fresh plasma was 0 per cent, 0.5 per cent, 1.0 per 
cent, 1.5 per cent, 1.75 per cent, and 2 per cent. 
Prothrombin consumption tests were then done as described 
above and the results plotted in Figure 1 (page 20). The 
abscissa was defined as AHG activity with 0.0 per cent con¬ 
centration of test plasma being taken as 0 AHG activity and 
2 per cent concentration of test plasma as 100 per cent AHG 
activity. From this graph the prothrombin consumptions 
determined above were converted to AHG activity. 
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As can be seen from Tables 1 to 8 and Figure 2, 
AHG activity as measured above appeared to be well preserved 
at 4° centigrade when ACD was used as an anticoagulant but 
was very unstable when versene was used as the anticoagulant. 
Factors such as type of container, whether the blood was 
agitated before storage and whether plasma was separated 
from red cells appeared to have no appreciable effect on the 
storage stability of AHG activity at least for the first 
three weeks. Also whether the donor was given heparin before 
the blood was collected did not appear to influence the 
results one way or the other. 
After three weeks all samples stored in ACD showed 
AHG activity above 75 per cent where as those stored in 
versene at 4° centigrade showed AHG activity of 0 per cent. 
In all the tested samples, fresh frozen plasma 
seemed to offer little, if any, advantage over plasma stored 
at 4° centigrade except where versene was used as an anti¬ 
coagulant and here fresh frozen plasma had a slight AHG 
activity after three weeks. 
As can be seen from Table 9 and Figure 3, AHG 
activity of stored Blood Bank blood as measured by the above 
method varied quite randomly and seemed to be completely 
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10 
independent of where the blood was collected and how long 
it had been stored, AHG activity ranged from 25 per cent to 
90 per cent. 
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PER GEM’ AHG ACTIVITY OF STORED PLASMA 












3 88% 88% 45$ k0% 
7 80% 80% 85$ 0% 0% 0% 
NOTE: Blood stored in siliconized 
test tubes. 








PER CENT AHG ACTIVITY OF STORED PLASMA 












3 90% 75% 10# U5% 
7 80% 70% 80% 0% 0% 10# 
NOTE: Blood stored in siliconized 
test tube. Donor also received 10 mg, 
of intravenous heparin five minutes 
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PER CENT AHG ACTIVITY OF STORED PLASMA 
ACD as Anticoagulant Versene as Anticoagulant 
Plasma 
Whole 





$5% 90% 40 % 10# 
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t)0 $5% &5% 0% Ofo 0% 








PER CENT AHG ACTIVITY OF STORED PLASMA 










3 85% 90% 1*5% 35% 
7 80% 88% 80% 0% 0% 10% 
NOTE: Blood stored in plastic bags. 
Donor also received 10 mg, of intra¬ 
































4 Hartford 30%, 
4 Hartford 60 % 
5 Hartford uo% 






5 Hartford 33% 
5 Hartford 73% 
3 New Haven 13% 
4 New Haven 30% 
4 New Haven 23% 
3 New Haven 63% 
6 New Haven 90% 
5 New Haven 73% 
5 New Haven 30% 
4 New Haven &3% 
6 New Haven 70% 
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CONVERSION OF PROTHROMBIN CONSUMPTION TO AHG ACTIVITY 
% PROTHROMBIN 
GRAPH REPRESENTS A STANDARD DILUTION CURVE FOR % OF NORMAL 
AHG ACTIVITY AS REPRESENTED BY PROTHROMBIN CONSUMPTION 
WHEN MIXED WITH THE BLOOD OF A HEMOPHILIAC 
PATIENT IN A RATIO OF I TO 50 
FIGURE 1 

EFFECT OF TYPE OF STORAGE CONTAINER ON AHG ACTIVITY 
WEEKS OF STORAGE 
EACH LINE REPRESENTS WHOLE BLOOD OBTAINED FROM SEPARATE 
DONORS AND STORED AT 4° C 
FSS-URE <2- 

AHG ACTIVITY OF STORED BLOOD BANK BLOOD 
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In the past few years, a host of agents has been 
investigated both for the management of bleeding emergencies 
and for prophylaxis against such episodes in hemophiliac 
patients in an attempt to find a readily available agent and 
one that would not be too expensive. These have included 
estrogens (17,IS), Hydergine (19,20) (a mixture of ergot 
alpaliods), intravenous histamine (21) oral vitamin E (22), 
oral thrombin (23) intravenous organic di iodo compounds 
(24), intravenous calcium (25), oral glycocoll combined with 
ascorbic acid and calcium (26), intravenous polyvirylpryrroli- 
done (27), oral cortisone (23), a concentrate made from human 
urine (29) and bovine AHG (30). However, there has been no 
confirming support for any of these agents and there has been 
no real rationale for their use. Therefore, one is forced to 
the conclusion that the only available agents effective in the 
management of hemophiliac patients are human blood and its 
derivatives. 
The results of this series of experiments show that 
there is a definite possibility that hemophiliac patients can 
be treated successfully with stored plasma since AHG activity 
seems to be fairly well preserved if the blood is collected 
very carefully and stored with ACD as an anticoagulant. This 
would mean that there could be readily available and at little 
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24 
cost, a constant supply of plasma for the treatment of 
hemophilia. 
From the work done in this project and from the 
work of others, it would appear that the most important 
factors involved in preserving the AHG activity of blood 
when stored at 4° centigrade are the type of anticoagulant 
used and the care used in collecting the blood. 
With respect to the type of anticoagulant, it has 
been shown by Spaet (2,8) that all AHG activity is lost 
within one week when blood is stored in oxalate. Since 
oxalate was routinely used up until recent years as the anti¬ 
coagulant for Blood Bank blood it is easy to see why stored 
plasma came into such disrepute as a means for treating 
hemophiliac patients. The results of this experiment also 
show that AHG activity is rapidily lost when blood is stored 
in versene. ACD on the other hand does not seem to interfere 
at all, with the AHG activity of blood or plasma stored at 
4° centigrade. 
The other important factor in preserving AHG 
activity seems to be the care with which the blood is 
collected. Brinkhaus (12,13) has shown that if blood is 
very carefully collected and preserved in ACD, the AHG 
activity is well maintained for periods up to three weeks 
when stored at 4° centigrade. The fact that AHG activity is 
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25 
well maintained in carefully collected blood may well be 
related to the fact that if care is taken in collecting the 
blood, small clots are not allowed to form. It was with 
this theory in mind that intravenous heparin was given to 
the donor before half of the samples were collected. How¬ 
ever, the fact that heparin did not appear to effect the 
results of AHG activity is understandable when it is realized 
that under the conditions of collecting the blood, there was 
little chance for clotting to occur. The other evidence 
obtained from this series of experiments, however, does add 
some weight to this theory. Since the blood was collected 
fairly rapidly and in small quantities there was very little 
opportunity for clotting to occur and there was very little 
loss of AHG activity in any of the samples stored in ACD 
over a period ranging from three to six weeks. On the other 
hand the stored Blood Bank blood which was collected routinely 
showed great variation with respect to AHG activity and it 
is a known fact that stored Bank blood often contains small 
clots of blood. Spaet (3)also found this variability in AHG 
activity of Blood Bank blood but he attributed this variation 
to an AHG inhibitor that was present in certain normal indivi¬ 
duals and that led to the fairly rapid loss of AHG activity. 
Since the first part of this experiment only used four differ¬ 
ent donors, one cannot be sure that Spaet’s postulated AHG 
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inhibitor does not exist. To show that the care in pre¬ 
venting any clotting to occur rather than the presence of 
an AHG inhibitor was responsible for the loss of AHG acitivity 
of Bank blood would require one to use a large number of 
donors. The blood would be collected as was done with the 
four donors in this experiment and then tested to see if 
AHG activity was retained uniformly all the blood samples or 
whether it showed a random variation as did stored Bank 
blood. Were this latter result the case, one would have to 
give further thought to the presence of an AHG inhibitor as 
postulated by Spaet. 
Another factor that has received some study as 
exerting influence on the AHG activity of blood stored at 
4° centigrade has been the type of container used. Penick 
and Brinkhaus (10) reported that AHG activity was inhanced 
by the use of containers with silicone surfaces. The results 
from the present experiments show that the type of storage 
container has little effect on AHG activity for the first 
three weeks of storage. However, for longer periods of time 
blood and plasma stored in plastic bags or siliconized test 
tubes seemed to retain AHG activity better than blood stored 
in glass containers. 
Other observations worthy of note are the effect 
of agitation and the effect of red blood cells on AHG 
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activity. Agitation did not appear to be detrimental at 
all, nor did the presence of red cells in spite of their 
known thromboplastic activity. 
From all that has been said, one cannot help but 
be optomistic with respect to the finding of a readily avail¬ 
able agent that can be used for the treatment of hemophilia. 
It would seem that fresh frozen plasma has nothing more to 
offer with respect to AHG activity than does blood stored 
under normal Blood Bank conditions if it is carefully collected 
and stored in ACD. If it should be found that if clotting 
occurring during the routine collection is the cause for the 
random low AHG values in stored blood, it is not inconceivable 
that blood donors, before donating, could receive intravenous 
heparin in order to insure a minimum of clotting. Since 
heparin was shown not to decrease AHG activity this could have 
no adverse effect on the storage stability of AHG activity. 
Thus hemophiliac patients, no matter where they were located, 
would have at the nearest hospital an available and relatively 
inexpensive source of plasma to combat any crises that might 
arise. 
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SUMMARY 
1. Plasma AHG activity of blood carefully collected in 
AGD solution and stored at 4° centigrade is well preserved 
for periods up to six weeks or longer, 
2. Non wetting surfaces appear to be superior to glass 
surfaces in the preservation of AHG activity of plasma 
stored at 4° centigrade for six weeks or longer, 
3. The AHG activity of plasma obtained from blood collected 
in versene and stored at 4° centigrade is destroyed rapidly, 
4. The sporadic loss of plasma AHG activity in blood collected 
for the Blood Bank and stored at 4° centigrade probably is 
due to partial blood clotting rather than the presence of an 
AHG inhibitor, 
3. The plasma AHG activity of stored blood is not effected 
by agitation, the presence of red blood cells or the presence 
of small amounts of heparin, 
6. The plasma from blood routinely collected into plastic 
bags containing ACD and stored at 4° centigrade for periods up 
to seven weeks should be as effective as fresh frozen plasma 
of comparable age in the treatment of bleeding hemophiliac 
patients. 
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